Comparison of the Combination of Fenofibrate and Simvastatin Versus Atorvastatin
NCT ID: NCT00362934
Last Updated: 2009-07-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
516 participants
INTERVENTIONAL
2006-10-31
2008-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of the Combination of Fenofibrate and 40 mg Simvastatin Versus 40 mg Simvastatin Monotherapy
NCT00352183
Comparison of the Combination of Fenofibrate and 20 mg Simvastatin Versus 40 mg Simvastatin Monotherapy
NCT00349375
Comparison of the Combination of Fenofibrate and Simvastatin Versus Pravastatin
NCT00362206
A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease
NCT01674712
A Controlled-Study of Fenofibrate 145 mg and Ezetimibe 10 mg in Type IIb Dyslipidemic Patients With Features of the Metabolic Syndrome
NCT00349284
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
fenofibrate / simvastatin
Combination of fenofibrate and simvastatin 20 mg and 40 mg
2
Atorvastatin
Atorvastatin 10 mg and 20mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fenofibrate / simvastatin
Combination of fenofibrate and simvastatin 20 mg and 40 mg
Atorvastatin
Atorvastatin 10 mg and 20mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pregnant or lactating women
* Contra-indication to fenofibrate or simvastatin or atorvastatin
* Unstable or severe cardiac disease
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Solvay Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Solvay Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Director Solvay
Role: STUDY_DIRECTOR
Solvay Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site 501
Haskovo, , Bulgaria
Site 505
Pleven, , Bulgaria
Site 503
Plovdiv, , Bulgaria
Site 506
Plovdiv, , Bulgaria
Site 500
Sofia, , Bulgaria
Site 502
Sofia, , Bulgaria
Site 504
Sofia, , Bulgaria
Site 507
Sofia, , Bulgaria
Site 509
Sofia, , Bulgaria
Site 511
Sofia, , Bulgaria
Site 508
Varna, , Bulgaria
Site 510
Varna, , Bulgaria
Site 109
Chrudim, , Czechia
Site 117
Havířov, , Czechia
Site 101
Olomouc, , Czechia
Site 114
Olomouc, , Czechia
Site 116
Ostrava, , Czechia
Site 107
Pardubice, , Czechia
Site 111
Pardubice, , Czechia
Site 113
Pilsen, , Czechia
Site 100
Prague, , Czechia
Site 104
Prague, , Czechia
Site 108
Prague, , Czechia
Site 110
Prague, , Czechia
Site 115
Prague, , Czechia
Site 103
Teplice, , Czechia
Site 106
Trutnov, , Czechia
Site 118
Uničov, , Czechia
Site 102
Ústí nad Orlicí, , Czechia
Site 203
Berlin, , Germany
Site 204
Bochum, , Germany
Site 205
Dresden, , Germany
Site 206
Görlitz, , Germany
Site 202
Hamburg, , Germany
Site 208
Karlsruhe, , Germany
Site 207
Leipzig, , Germany
Site 201
Magdeburg, , Germany
Site 209
Nuremberg, , Germany
Site 200
Unterschneidheim, , Germany
Site 301
Banská Bystrica, , Slovakia
Site 307
Bratislava, , Slovakia
Site 310
Bratislava, , Slovakia
Site 311
Bratislava, , Slovakia
Site 312
Bratislava, , Slovakia
Site 309
Dolný Kubín, , Slovakia
Site 302
Košice, , Slovakia
Site 305
Lučenec, , Slovakia
Site 306
Nitra, , Slovakia
Site 304
Nové Zámky, , Slovakia
Site 308
Prešov, , Slovakia
Site 303
Vráble, , Slovakia
Site 300
Žilina, , Slovakia
Site 416
Donetsk, , Ukraine
Site 401
Kharkiv, , Ukraine
Site 412
Kiev, , Ukraine
Site 402
Kyiv, , Ukraine
Site 404
Kyiv, , Ukraine
Site 408
Kyiv, , Ukraine
Site 410
Kyiv, , Ukraine
Site 414
Lutsk, , Ukraine
Site 406
Lviv, , Ukraine
Site 407
Odesa, , Ukraine
Site 409
Odesa, , Ukraine
Site 411
Odesa, , Ukraine
Site 405
Simferopol, , Ukraine
Site 413
Uzhhorod, , Ukraine
Site 400
Vinnitsa, , Ukraine
Site 415
Zaporizhzhya, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2006-000519-21
Identifier Type: -
Identifier Source: secondary_id
C LF0242780-01 05 03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.